Chronic treatment with myo-inositol reduces white adipose tissue accretion and improves insulin sensitivity in female mice.
Type 2 diabetes is a complex disease characterized by a state of insulin resistance in peripheral tissues such as skeletal muscle, adipose tissue or liver. Some inositol isomers have been reported to possess insulin-mimetic activity and to be efficient in lowering blood glucose level. The aim of the present study was to assess in mice the metabolic effects of a chronic treatment with myo-inositol, the most common stereoisomer of inositol. Mice given myo-inositol treatment (0.9 or 1.2 mg g(-1) day(-1), 15 days, orally or intraperitoneally) exhibited an improved glucose tolerance due to a greater insulin sensitivity. Mice treated with myo-inositol exhibited a decreased white adipose tissue accretion (-33%, P<.005) compared with controls. The decrease in white adipose tissue deposition was due to a decrease in adipose cell volume (-33%, P<.05), while no change was noticed in total adipocyte number. In skeletal muscle, in vivo as well as ex vivo myo-inositol treatment increased protein kinase B/Akt phosphorylation under baseline and insulin-stimulated conditions, suggesting a synergistic action of myo-inositol treatment and insulin on proteins of the insulin signalling pathway. Myo-inositol could therefore constitute a viable nutritional strategy for the prevention and/or treatment of insulin resistance and type 2 diabetes.
Lyon University, Oullins, France. marine.croze@insa-lyon.fr
Marine L
ML
Croze
Roxane E
RE
Vella
Nicolas J
NJ
Pillon
Hédi A
HA
Soula
Lilas
L
Hadji
Michel
M
Guichardant
Christophe O
CO
Soulage
D017667:Adipocytes / Q000187:drug effects; D052436:Adipose Tissue, White / Q000166:cytology / Q000187:drug effects*; D000284:Administration, Oral; D000818:Animals; D005260:Female; D005951:Glucose Tolerance Test; D007294:Inositol / Q000494:pharmacology*; D007328:Insulin / Q000378:metabolism; D007333:Insulin Resistance / Q000502:physiology; D000078790:Insulin Secretion; D051379:Mice; D018482:Muscle, Skeletal / Q000187:drug effects; D051058:Oncogene Protein v-akt / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects
D007328:Insulin; D007294:Inositol; D051058:Oncogene Protein v-akt